Juglanin Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

418.35

Methanol: 16mg/mL (38.25mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

C20H16O10

O=C1C(O[C@@H]2O[C@@H](CO)[C@](O)[C@]2O)=C(C3=CC=C(O)C=C3)OC4=CC(O)=CC(O)=C41

5041-67-8

Breast cancer cells are plated in 96-well plates with a density of 5x10^3cells/well. After 12 h, the cells are treated with different concentrations of Juglanin (0 to 40uM) for different periods of time (24 hours and 48 h). Then the fresh mixture of MTS and PMS is added and incubated for 4 hours at 37 degree C according to the manufacturer's protocol. A microplate reader is conducted to determine the absorbance at 500nM, and the IC50 values are assessed with the probit model. Each one is performed in triplicate.

Juglanin inhibits the proliferation of breast cancer cells in a dose- and time-dependent manner and presents less cytotoxic against the normal cells. Juglanin results in the accumulation of cancer cells in the G2/M phase and a corresponding decrease in G0/G1 and S phases in both MCF-7 and SKBR3 cells. Juglanin up-regulates the expressions of phosphorylated Chk2, Chk2, phosphorylated Cdc25C, phosphorylated Cdc2, p27, cyclin D and down-regulates the levels of Cdc25C as well as Cdc2. The proportion of apoptosis is negligible for control cells, whereas 24 hours of exposure of cells to Juglanin leads to a dose-dependent increase of apoptotic cells in both MCF-7 and SKBR3 cells. Juglanin significantly suppresses the anti-apoptotic factor of Bcl-2 expression, and in contrast Bad and Bax are both up-regulated for Juglanin treatment, Juglanin markedly activates caspases and leads to Caspase-9, Caspase-8, and Caspase-3 cleavage. ROS generation is initiated by Juglanin and significantly increased by high concentrations of Juglanin. Juglanin also increases the level of JNK phosphorylation in both MCF-7 and SKBR3 cells.

MAPK; JNK